Gol Linhas (GOL) To Start Flights To Aracatuba In November

Gol Linhas Aereas Inteligentes S.A. (NYSE:GOL) has announced non-stop daily flights to Araçatuba as part of its expansion plan in the state of São Paulo. Following the launch of these direct flights in November, the company will serve a total of 75 destinations.

Flights to São Paulo’s Guarulhos International Airport will be operated on the Boeing (NYSE:BA) 737-700 Next Generation aircraft, featuring all modern amenities, such as entertainment services, in-flight internet service, complementary snacks and drinks etc. The Boeing 737 jet will have the largest capacity plying on the route, carrying up to 138 passengers.

This route extension marks the seventh regional destination announced by the carrier in 2019. Earlier this March, the airline announced regular flights to the cities of Cascavel, Passo Fundo, Vitória da Conquista, Sinop, Franca and Barretos. These services also form part of the company’s plans to increase operations in São Paulo as well as reduction of the state taxes on jet fuel (an important initiative for the development of the country's air travel).

Zacks Rank & Key Picks

Gol Linhas carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader Transportation sector are SkyWest, Inc. (NASDAQ:SKYW) , GATX Corporation (NYSE:GATX) and Trinity Industries, Inc. (NYSE:TRN) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Shares of SkyWest have surged more than 34% so far this year. Meanwhile, both GATX and Trinity flaunt an encouraging earnings history. While GATX outperformed the Zacks Consensus Estimate in each of the trailing four quarters, Trinity surpassed estimates in three of the preceding four quarters.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>